AB Science CEO Discusses New Early-Treatment Drug For Covid-19 | Interview

Alain Moussy, CEO of AB Science, discusses their new early-treatment drug for COVID-19

AB Science | https://www.ab-science.com/Article on drug published in Science | https://www.science.org/doi/10.1126/science.abg5827


Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee